Koers Sinopharm Group Co., Ltd. Other OTC
Aandelen
SHTDY
US82937K1016
Farmaceutische producten
Omzet 2024 * | 649 mld. 90,04 mld. 83,55 mld. | Omzet 2025 * | 707 mld. 98,08 mld. 91 mld. | Marktkapitalisatie | 58,54 mld. 8,12 mld. 7,54 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 9,61 mld. 1,33 mld. 1,24 mld. | Nettowinst (verlies) 2025 * | 10,58 mld. 1,47 mld. 1,36 mld. | EV/omzet 2024 * | 0,11 x |
Nettoschuld 2024 * | 11,49 mld. 1,59 mld. 1,48 mld. | Nettoschuld 2025 * | 9,36 mld. 1,3 mld. 1,2 mld. | EV/omzet 2025 * | 0,1 x |
K/w-verhouding 2024 * |
6,08
x | K/w-verhouding 2025 * |
5,53
x | Werknemers | - |
Dividendrendement 2024 * |
4,98% | Dividendrendement 2025 * |
5,47% | Vrij verhandelbaar | 42,99% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Yong Liu
PSD | President | 55 | 09-01-09 |
Shuang Jun Xu
PRN | Corporate Officer/Principal | 55 | 01-03-11 |
Zhong Xi Cai
PRN | Corporate Officer/Principal | 59 | 01-05-10 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Qi Yu Chen
BRD | Director/Board Member | 52 | 01-05-10 |
Xiao Hui Guan
BRD | Director/Board Member | 53 | 11-01-19 |
Yi Jian Wu
SEC | Corporate Secretary | 54 | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,05% | 69,5 mld. | |
-1,82% | 24,09 mld. | |
+8,13% | 8,2 mld. | |
-18,28% | 7,97 mld. | |
+19,12% | 4,32 mld. | |
0,00% | 4,19 mld. | |
-3,30% | 3,89 mld. | |
+23,97% | 3,62 mld. | |
+8,64% | 3,41 mld. |